Background/aims: The clearance of moxifloxacin is reported to be unaltered in the presence of renal insufficiency. There is little information about the clearance of intravenous moxifloxacin in renal replacement therapies during intensive care. The aim of this study was to determine the clearance of moxifloxacin during continuous veno-venous haemofiltration (CVVHF) in vitro.
Introduction
Moxifloxacin is a broad-spectrum fluoroquinolone. 1 It belongs to a group of quinolones known as 8-methoxy fluoroquinolones and is effective against both Gram-positive and Gram-negative bacteria. 1 Moxifloxacin, when taken orally, is well absorbed with an absolute bioavailability of 90%. Approx. 45% is bound to serum proteins, independent of concentration. 1 The renal clearance of moxifloxacin in healthy subjects is 24-53 mL/min and the total body clearance is 179-246 mL/min. 2 Moxifloxacin is metabolized through glucuronide and sulphate conjugation and 19% is excreted unchanged in the urine. 1 The area under the concentration-time curve (AUC) and peak concentration of moxifloxacin may be reduced in patients with mild hepatic insufficiency. The pharmacokinetics in patients with mild, moderate or severe renal impairment are not significantly altered. 3 Continuous veno-venous haemofiltration (CVVHF) is an established method of continuous renal replacement therapy that offers high haemodynamic stability, optimal control of circulating volume and effective removal of metabolic products and drugs. 4 For all antibiotics, pharmacokinetic data are needed for adjustment of dose and dosage interval to provide effective concentrations at the site of infection, as well as to avoid accumulation.
Recently, Fuhrmann et al. 5 found that the pharmacokinetics of moxifloxacin in nine critically ill patients with acute renal failure during CVVHDF were comparable to those in patients without 
Methods

Model of CVVHF
In vitro models of renal displacement therapies are well suited to experiments on evaluation of drug removal. 6, 7 We used an in vitro extracorporeal circuit, originating from and terminating in a Y-shaped double-lumen catheter, which was inserted in a reservoir filled with a mixture of human blood (600 mL of washed human erythrocytes), 100 mL of 8.4% NaHCO 3 and various amounts of Ringer solution and human albumin to give a total volume of 1000 mL (pH 7.35 -0.5, haematocrit 41 -2). Blood was driven through the circuit by means of an Edwards BM 11 post-dilution haemofiltration system using SH-Bic 35 filtration solutions and Hospal Multiflow 100 haemofilters (AN69 HF, acrylonitrile sodium methallylsulphonate hollow-fibre, surface area of 0.9 m 2 , priming volume of the filter 65 mL, line dead-volume of 75 mL). All experiments were performed at the same place in an air-conditioned room in the Department of Transfusion Medicine (22 C). Blood samples were centrifuged (Heraeus Megafuge 1.0R, 3000g) after sampling and stored together with ultrafiltrate samples at -20 C. To ensure that the mixtures of blood could not influence the pharmacokinetics of moxifloxacin, we added 15 mg of moxifloxacin to 10 mL of the experiments' blood mixtures (nominal concentration 1.5 mg/mL) (see below) and compared each with a mixture of 15 mg of moxifloxacin and 10 mL of fresh human blood (nominal concentration 1.5 mg/mL).
HPLC
A modified method for detecting moxifloxacin in plasma and dialysate was used. 8 The (2) column (Phenomenex, Aschaffenburg, Germany) equipped with a 4 · 3 mm pre-column. The gradient started at a flow rate of 1 mL/min with 10% solvent B. It changed linearly after 1 min to 30% B at 10 min. One hundred microlitres of plasma or dialysate was treated with 10 mL (109 ng) of internal standard ofloxacin and 1.8 mL of -20 C cold acetonitrile. Samples were centrifuged for 10 min at 13 000 rpm and the supernatant was transferred into conical glass tubes. After evaporation at 50 C in a stream of nitrogen the residual was resolved in 100 mL of solvent A, centrifuged again and transferred into 300 mL microvials. Twenty microlitres was injected into the HPLC. The limit of detection was at 12.4 ng/100 mL extracted plasma and inter-and intra-day variability were below 5% at a spike level of 1.75 mg/mL plasma.
Experiments
In all experiments, we had a net fluid balance of -0 L/h; in experiments 1-4, a turnover rate of 2 L/h (post-dilution with 2 L/h, filtration rate of 2 L/h) and in experiment 5 a turnover rate of 1 L/h (post-dilution with 1 L/h, filtration rate of 1 L/h). Therefore, we had no dilution or concentration of the reservoir content. Details of the experiments are shown in Table 1 .
Calculations
The AUCs of the moxifloxacin concentrations were calculated with the computer program Kinetica 2000 (www.innaphase.com). Calculation of filtrate clearances (CL f ; CL f = C f · Q f /Ca; C f = filtrate concentration, Q f = filtration rate = rate of filtration fluid crossing the filter, Ca = arterial serum concentration), sieving coefficients (SC; SC = C f /Ca), Table 1 
Results
Blood mixtures of the experiments had no influence on moxifloxacin stability (1.487 -0.1 mg/mL) compared with fresh human blood (1.479 -0.1 mg/mL, P = 0.83).
Experiment 1
The filter needed a priming time of about 20 min to achieve a stable haemofiltration situation. About 3 mg of moxifloxacin was absorbed during this run-in period ( Figure 1 , Table 2 ). The sieving coefficient was only 0.64 and the filtration clearance only 21.3 mL/min (blood flow 100 mL/min, turnover 2 L/h) ( Figure 1 , Table 2 ).
Experiment 2
Priming of the filter as before; we had stable filtration conditions and found a sieving coefficient of 0.90 and a filtration clearance of moxifloxacin of 29.9 mL/min (blood flow 100 mL/min, turnover 2 L/h) ( Figure 1 , Table 2 ).
Experiment 3
Filter priming and filtration without albumin resulted in a sieving coefficient of 1.07 and a filtration clearance of moxifloxacin of 35.7 mL/min (blood flow 100 mL/min, turnover 2 L/h) ( Figure 1 , Table 2 ).
Experiment 4
Priming of the filter and increasing the albumin concentration to 40 g/L achieved a sieving coefficient of 0.80 and a filtration clearance of moxifloxacin of 26.6 mL/min (blood flow 100 mL/min, turnover 2 L/h) ( Figure 1 , Table 2 ).
Experiment 5
Priming of the filter and decreasing the blood flow from 100 mL/ min to 50 mL/min and the turnover rate from 2 L/h to 1 L/h resulted in marked reduction of the filtration clearance of moxifloxacin to 15.2 mL/min. The sieving coefficient was 0.91 ( Figure 1 , Table 2 ). Table 1 . SC, sieving coefficient; CL f , filtration clearance. SC, sieving coefficient (C f /Ca, C f = filtrate concentration, Ca = arterial serum concentration); CL f , filtration clearance (C f · Q f /Ca, C f = filtrate concentration, Q f = filtration rate, Ca = arterial serum concentration); Q f · C f , recovery in the filtrate; Ca · Qb -Cv · Qb, elimination of the drug from the blood circuit (Qb = blood flow rate, Cv = venous serum concentration).
The recovery in the ultrafiltrate and the elimination of moxifloxacin from the blood circuit are presented in Table 2 . After filter priming, the recovery of moxifloxacin in the filtrate exceeds the moxifloxacin elimination from the blood circuit in experiments 2-5.
Discussion
The clearance of moxifloxacin was unaltered in the presence of renal insufficiency following single oral doses in one study, suggesting lack of need for dose adjustment. 1 Recently, Fuhrmann et al. 5 indicated that the filtration clearance of 27 mL/min and the total body clearance of 318 mL/min of moxifloxacin in critically ill patients with acute renal failure undergoing CVVHDF was comparable to that in healthy subjects and patients without renal impairment.
The main findings in our study were normal moxifloxacin filtration clearances of 23-38 mL/min during CVVHF in vitro. During CVVHF, the physiological renal tubular reabsorption is lacking. Normal moxifloxacin clearance with a lower haemofiltration rate (2 L/h, about 33 mL/min) compared with the physiological glomerular filtration rate (about 100 mL/min) shows that a drug such as moxifloxacin can be excreted by CVVHF with a similar efficiency to the normal kidney. We achieved this clearance with a turnover rate of 2 L/h (post-dilution fluid of 2 L/h and filtration rate of 2 L/h, blood flow 100 mL/min). This is in accordance with the usual standard setting during CVVHF (blood flow 125 mL/min, filtration rate 1.5 L/h). 4 Fuhrmann et al. 5 used a continuous diafiltration method with a dialysate flow of 1 L/h and a mean turnover rate of 1 L/h (pre-dilution fluid of 1 L/h and filtration rate of 1 L/h, blood flow 150 mL/min). We found a reduced haemofiltration clearance of 15 mL/min with this filtration setting without an additional dialysis circuit. This argues for a comparable removal of moxifloxacin over the dialysate circuit with a flow of 1 L/h.
We can only speculate about the influence of the pre-dilution supply (Fuhrman study) versus our post-dilution supply. Supplying the solution before the filter is added lowers the blood viscosity but reduces the filter efficiency and increases the cost of haemofiltration, because a proportion of the generated filtrate is simply replacement fluid. 4 On comparison of the filtration clearances, it appears that there is no clinically relevant difference.
The run-in experiment with the haemofilter showed a delay of about 20 min until stable filtration was achieved. Compared with the experiments after priming of the filter, an absorption of about 3 mg of moxifloxacin was achieved, which is clinically irrelevant in terms of a standard dose of 400 mg of moxifloxacin in a patient. In the filtration phase after priming in experiment 1, the Cv and the Cf concentrations exceed Ca concentrations. The cell debris in the filter during priming has obviously absorbed moxifloxacin and released it later. In experiments 2-5 after priming, the recovery of moxifloxacin in the filtrate exceeds the moxifloxacin elimination from the blood circuit. The definitive release of moxifloxacin from cell deposits into the filtrate/venous line is not clear, since we did not investigate this situation with a moxifloxacin-free reservoir after priming.
Compared with clinical reality (patients with 400 mg of moxifloxacin), in vitro haemofiltration experiments are limited because the reservoir (with a small blood volume and a small amount of a drug) has no connections to tissue compartments. Other possible factors responsible for differences in calculated sieving coefficients, based on the fraction of unbound drug in plasma versus measured sieving coefficients are: flow rates, drug concentrations, solvent systems and dilution techniques. [9] [10] [11] The protein concentrations had a minor influence on the sieving coefficients and filtration clearances. These results could indicate that moxifloxacin is filtered nearly as freely as creatinine and therefore nearly independently of the blood protein concentration.
12
Of other fluoroquinolones investigated (ciprofloxacin, ofloxacin, enoxacin, pefloxacin), dosage adjustment during CVVHF has been recommended only for ofloxacin based on protein-binding data in healthy volunteers and on pharmacokinetic data in patients with chronic renal failure. 13 On the other hand, in a study with levofloxacin (protein binding of only 35%) during CVVHF in intensive care patients it was shown that blood protein concentration had an influence on the sieving rate. 14 Unfortunately, in vitro haemofiltration experiments have no predictive power for intensive care patients with a restricted hepatic function. Hepatic clearance has an important impact on the total body clearance of moxifloxacin.
1 A main determinant of hepatic clearance of drugs is liver blood flow, which is compromised in intensive care patients with severe heart failure or septic shock. 15 In conclusion, this in vitro study supports the finding 5 that moxifloxacin during CVVHF with a standard turnover rate has the same filtration clearance as renal clearance in healthy volunteers and patients without renal or hepatic disease and is nearly independent of blood protein concentrations.
This confirms that 400 mg of moxifloxacin iv can be recommended once daily in anuric patients during continuous venovenous replacement therapies. 5, 12 
